CAR-T细胞疗法在肿瘤治疗中的研究及展望
摘要
近年来,肿瘤免疫疗法的兴起,为肿瘤患者提供了更可靠的治疗方案。其中,CAR-T细胞疗法是目前应用最为广泛的免疫疗法之一。然而,随着该疗法的广泛研究及应用,与之相应的不良反应等问题也逐渐给大家带来了挑战。现就CAR-T细胞疗法在肿瘤治疗中的应用及不良反应做一简述。
引文
[1] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science, 2013, 342(6165):1432-1433.
[2]王思佳. CAR-T疗法技术发展综述[J].科学与创新,2018,(15):56-59
[3] Chmielewski M,Abken H. Trucks:The fourth generation of cars[J]. Expert Opin Biol Ther, 2015, 15(8):1145-1154.
[4]Makita S,Yoshimura K,Tobinai K. Clinical development of anti-cd19 chimeric antigen receptor T-cell therapy for B-cell non-hodgkin lymphoma[J]. Cancer Sci,2017,108(6):1109-1118.
[5] Kochenderfer JN,Wilson WH,Janik JE,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood,2010,116(20):4099-4102.
[6]张志伟,何江川,金华君,钱其军..基于CA R-T细胞的联合治疗策略在实体瘤中的研究新进展[J].实用肿瘤杂志,2018,33(4):304-308
[7]PORTER D L,LEVINE B L,KALOS M,et al Chimeric antigen receptlr-modified T cells in chronic lymphoid leukemia[J],N Engl J Med,2011,365(8):725-733
[8]Park JH, Riviere I, Wang XY, Bernal Y, Purdon T, Halton E, et al. Implications of minimal residual disease negative complete remission(MRD-CR)and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood 2015; 126:682.
[9]HASO W,LEE DW,SHAH N N,et al.Anti-CD22-chimeric antigen receptors targeting B-cell preeursor acrte lymphoblastic leukemia[J].Blood,2013,121(7):1165-1174.
[10]GIORDANO ATTLANESE G M,MARIN V,HOYOS V, et al. In vivo model of a novel et al. approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor[J].Blood,2011,117:4736-4745.
[11]Mihara K,Yanagihara K,Takigahira M A, et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma[J],Br J Haemarol,2010,151(1):37-46.
[12]Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N,Figueroa A, et al. Chimeric antigen receptor engineering:a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 2015; 34(2):154-87.
[13]Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(95):95ra73.
[14] BrentjensR, YehR, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells:case report of an unforeseen adverse event in a phase I clinical trial[J]. Mol Ther,2010,18(4):666-668.
[15] Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348(6230):74-80.
[16] Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375(26):2561-9.
[17]林才瑶,Muhammad Kalim,梁可莹,詹金彪.CAR-T疗法及其在肿瘤免疫治疗中的应用进展[J].中国细胞生物学学报,2018,40(3):412-427
[2]王思佳. CAR-T疗法技术发展综述[J].科学与创新,2018,(15):56-59
[3] Chmielewski M,Abken H. Trucks:The fourth generation of cars[J]. Expert Opin Biol Ther, 2015, 15(8):1145-1154.
[4]Makita S,Yoshimura K,Tobinai K. Clinical development of anti-cd19 chimeric antigen receptor T-cell therapy for B-cell non-hodgkin lymphoma[J]. Cancer Sci,2017,108(6):1109-1118.
[5] Kochenderfer JN,Wilson WH,Janik JE,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood,2010,116(20):4099-4102.
[6]张志伟,何江川,金华君,钱其军..基于CA R-T细胞的联合治疗策略在实体瘤中的研究新进展[J].实用肿瘤杂志,2018,33(4):304-308
[7]PORTER D L,LEVINE B L,KALOS M,et al Chimeric antigen receptlr-modified T cells in chronic lymphoid leukemia[J],N Engl J Med,2011,365(8):725-733
[8]Park JH, Riviere I, Wang XY, Bernal Y, Purdon T, Halton E, et al. Implications of minimal residual disease negative complete remission(MRD-CR)and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood 2015; 126:682.
[9]HASO W,LEE DW,SHAH N N,et al.Anti-CD22-chimeric antigen receptors targeting B-cell preeursor acrte lymphoblastic leukemia[J].Blood,2013,121(7):1165-1174.
[10]GIORDANO ATTLANESE G M,MARIN V,HOYOS V, et al. In vivo model of a novel et al. approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor[J].Blood,2011,117:4736-4745.
[11]Mihara K,Yanagihara K,Takigahira M A, et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma[J],Br J Haemarol,2010,151(1):37-46.
[12]Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N,Figueroa A, et al. Chimeric antigen receptor engineering:a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 2015; 34(2):154-87.
[13]Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(95):95ra73.
[14] BrentjensR, YehR, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells:case report of an unforeseen adverse event in a phase I clinical trial[J]. Mol Ther,2010,18(4):666-668.
[15] Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348(6230):74-80.
[16] Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375(26):2561-9.
[17]林才瑶,Muhammad Kalim,梁可莹,詹金彪.CAR-T疗法及其在肿瘤免疫治疗中的应用进展[J].中国细胞生物学学报,2018,40(3):412-427